eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.
Location: United States, California, San Diego
Employees: 11-50
Phone: +1 858-546-3997
Total raised: $123.6M
Founded date: 2012
Investors 6
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | Mission Bi... | missionbio... |
| - | The Column... | thecolumng... |
| - | Abingworth... | abingworth... |
| - | Altitude L... | altitudels... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.07.2017 | Series C | $38.6M | - |
| 22.12.2015 | Series B | $40M | - |
| 20.05.2013 | Series A | $45M | - |
Mentions in press and media 19
| Date | Title | Description |
| 08.06.2023 | eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings | - |
| 08.06.2023 | eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings | eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules /EIN News/ -- SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in... |
| 10.01.2018 | Biopharma watchers arrive at rare consensus: 2018 will be big year for M&A | Not one person said they expect total M&A activity to decline in the coming year, relative to 2017. Just over 12 percent predicted deal activity would be comparable; the rest are expecting some sort of buying spree. Why? It’s not rocket... |
| 24.07.2017 | eFFECTOR Therapeutics Inks $38.6M Series C | SAN DIEGO, CA, Leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. >> Click here for more funding data on eFFECTOR The... |
| 24.07.2017 | eFFECTOR Therapeutics Closes $38.6M Series C Financing | eFFECTOR Therapeutics, Inc., a San Diego, CA-based developer of selective translation regulators for the treatment of cancer, raised $38.6M in Series C financing. The round was led by Pfizer Venture Investments (PVI) with participation from... |
| 24.07.2017 | eFFECTOR Therapeutics Raises $38.6M | San Diego-based eFFECTOR Therapeutics, a developer of treatments for cancer, has raised $38.6M in a Series C funding round, the company announced this morning. The funding was led by Pfizer Venture Investments (PVI), and also included Alexa... |
| 19.02.2016 | effector Therapeutics Increases Series B Financing to $56M | eFFECTOR Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company developing selective translation regulators for the treatment of cancer, increased its Series B financing to a total of $56M. The new funding came from Sectoral As... |
| 19.02.2016 | eFFECTOR Therapeutics Boosts Series B To $56M | San Diego-based eFFECTOR Therapeutics, which is developing gene translation technology to help in the treatment of cancer, has boosted its Series B funding to $56M, the company said Friday. The company--which raised $40M in the round back i... |
| 19.02.2016 | Effector Therapeutics bumps up Series B to $56M | The company says that eFT508 can regulate a number of cancer-driving and immune-signaling pathways – designed to restore translational control to stop disease progression. Promoted Covid-19’s terrible toll on diabetes patients. What can be ... |
| 22.12.2015 | Daily funding roundup - December 22, 2015 | Axonics completed $38.5M; Shuttl raised $20M; NextInput Inc., received $8M funding Motorola Solutions has made a strategic investment in BlueLine Grid, an emerging technology company that previously received an investment from In-Q-Tel, the... |
Show more